Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Tekni-Plex Begins Production At New China Manufacturing Facility August 28, 2017 Clinical-Stage Biotech Stock Might Outperform Amgen February 8, 2018 Incysus Announces Formation Of Scientific Advisory Board August 23, 2017
